Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

GENE:

CREBBP (CREB binding protein)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Entrez ID:

Related tests:

5-genomic mutation signature	Non Small Cell Lung Cancer	5-genomic mutation signature	Non Small Cell Lung Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
EGFR mutation + CREBBP mutation	Non Small Cell Lung Cancer	EGFR mutation + CREBBP mutation	Non Small Cell Lung Cancer	cisplatin + vinorelbine tartrate Resistant: B - Late Trials cisplatin + vinorelbine tartrate Resistant : B	cisplatin + vinorelbine tartrate Resistant: B - Late Trials cisplatin + vinorelbine tartrate Resistant : B
EGFR mutation + CREBBP mutation	Non Small Cell Lung Cancer	EGFR mutation + CREBBP mutation	Non Small Cell Lung Cancer	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B	gefitinib Sensitive: B - Late Trials gefitinib Sensitive : B
CREBBP mutation	Diffuse Large B Cell Lymphoma	CREBBP mutation	Diffuse Large B Cell Lymphoma	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3	ibrutinib Sensitive: C3 – Early Trials ibrutinib Sensitive : C3
CREBBP mutation	Colorectal Cancer	CREBBP mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CREBBP mutation	Colorectal Cancer	CREBBP mutation	Colorectal Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
CREBBP mutation	Diffuse Large B Cell Lymphoma	CREBBP mutation	Diffuse Large B Cell Lymphoma	R-CHOP Sensitive: C3 – Early Trials R-CHOP Sensitive : C3	R-CHOP Sensitive: C3 – Early Trials R-CHOP Sensitive : C3
EGFR mutation + CREBBP mutation	Lung Non-Small Cell Squamous Cancer	EGFR mutation + CREBBP mutation	Lung Non-Small Cell Squamous Cancer	EGFR inhibitor + Tyrosine kinase inhibitor Resistant: C3 – Early Trials EGFR inhibitor + Tyrosine kinase inhibitor Resistant : C3	EGFR inhibitor + Tyrosine kinase inhibitor Resistant: C3 – Early Trials EGFR inhibitor + Tyrosine kinase inhibitor Resistant : C3
CREBBP mutation	Bladder Cancer	CREBBP mutation	Bladder Cancer	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3	Immunotherapy Sensitive: C3 – Early Trials Immunotherapy Sensitive : C3
KAT6A-CREBBP fusion + FLT3-TKD mutation	Acute Myelogenous Leukemia	KAT6A-CREBBP fusion + FLT3-TKD mutation	Acute Myelogenous Leukemia	cytarabine + midostaurin + daunorubicin Sensitive: C4 – Case Studies cytarabine + midostaurin + daunorubicin Sensitive : C4	cytarabine + midostaurin + daunorubicin Sensitive: C4 – Case Studies cytarabine + midostaurin + daunorubicin Sensitive : C4
CREBBP mutation	Follicular Lymphoma	CREBBP mutation	Follicular Lymphoma	YF2 Sensitive: D – Preclinical YF2 Sensitive : D	YF2 Sensitive: D – Preclinical YF2 Sensitive : D
CREBBP deletion	Triple Negative Breast Cancer	CREBBP deletion	Triple Negative Breast Cancer	CDK4 inhibitor + CDK6 inhibitor Sensitive: D – Preclinical CDK4 inhibitor + CDK6 inhibitor Sensitive : D	CDK4 inhibitor + CDK6 inhibitor Sensitive: D – Preclinical CDK4 inhibitor + CDK6 inhibitor Sensitive : D